An allogeneic platform designed to generate First-In-Class Tumors antigen-focused immunotherapies.
Changing a paradigm in oncology
Our mission at Brenus is to provide a solution to patients with cold solid tumors – today’s biggest, unmet need in oncology.
Strict and AI assisted selection of Specific allogeneic Tumor cell lines to be the most representative of the targeted indication.
Selection criteria of starting material (Allogeneic tumor cell lines)
STC technology educates patient’s immune system with the widest range of tumor related AG linked to mechanism of relapse.